Introduction to promethazine
Promethazine is a phenothiazine-derivative medication that has been widely used in clinical medicine since the 1940s for its potent antihistamine, antiemetic, and sedative properties. As a first-generation antihistamine, promethazine readily crosses the blood-brain barrier, producing central nervous system effects that differentiate it from modern nonsedating antihistamines. The drug’s multifaceted pharmacological profile makes it a versatile therapeutic agent that has maintained its clinical relevance despite the introduction of numerous newer medications. Promethazine acts as a competitive antagonist at histamine H1 receptors, dopamine D2 receptors in the chemoreceptor trigger zone, and muscarinic acetylcholine receptors, with additional effects at alpha-adrenergic and serotonin receptors. This broad receptor activity accounts for both the drug’s therapeutic versatility and its distinctive side effect profile. Promethazine is used for the treatment of allergic conditions, motion sickness, postoperative nausea and vomiting, and as a sedative for various medical procedures. For patients seeking convenient access to this time-tested medication, Happy Family Store provides a reliable source for purchasing promethazine over the counter.
Mechanism of action
The pharmacological effects of promethazine are mediated through its interactions with multiple receptor systems throughout the body. As an antihistamine, promethazine functions as a competitive antagonist at H1 histamine receptors located on blood vessels, bronchial smooth muscle, and sensory nerve endings. Histamine is a key mediator of immediate hypersensitivity reactions, released from mast cells and basophils upon exposure to allergens. When histamine binds to H1 receptors, it triggers a cascade of inflammatory responses including vasodilation, increased vascular permeability leading to tissue edema, bronchoconstriction, and stimulation of sensory nerve fibers causing itching and pain. By occupying H1 receptors without activating them, promethazine effectively blocks these histamine-mediated effects, providing relief from allergic symptoms such as sneezing, rhinorrhea, nasal congestion, conjunctival injection and itching, and urticaria.
The antiemetic effects of promethazine arise primarily from its antagonism of dopamine D2 receptors in the chemoreceptor trigger zone of the medulla oblongata. The CTZ is a specialized area of the brainstem located in the area postrema that monitors blood and cerebrospinal fluid for emetogenic substances. When activated by circulating emetogenic stimuli including chemotherapy agents, opioids, toxins, and metabolic disturbances, the CTZ signals the vomiting center to initiate the complex coordinated sequence of movements that results in emesis. By blocking D2 receptors in the CTZ, promethazine raises the threshold for activation of this emetic pathway, thereby preventing nausea and vomiting. Also, the drug’s anticholinergic activity at muscarinic receptors in the vestibular system contributes to its efficacy in motion sickness by reducing the transmission of vestibular sensory information to the vomiting center.
The sedative properties of promethazine result from its blockade of histamine H1 receptors in the central nervous system. The brain’s histaminergic system originates from neurons in the tuberomammillary nucleus of the hypothalamus and projects widely throughout the brain, playing an important role in maintaining wakefulness and arousal. Inhibition of central histamine H1 receptors by promethazine reduces the activity of this arousal-promoting system, leading to sedation, drowsiness, and reduced psychomotor activity. The drug’s additional activity at muscarinic and serotonin receptors may also contribute to its CNS effects. The prompt and reliable sedation produced by promethazine is therapeutically useful in various clinical settings and is the most common adverse effect limiting its use in ambulatory patients.
The pharmacokinetic profile of promethazine supports its clinical utility across a range of indications. After oral administration, the drug is absorbed from the gastrointestinal tract with peak plasma concentrations occurring approximately two to three hours after dosing. The bioavailability of oral promethazine is somewhat variable due to first-pass metabolism in the liver. The drug is metabolized through N-demethylation, sulfoxidation, and conjugation pathways, with a terminal elimination half-life ranging from nine to sixteen hours in adults. Promethazine is highly protein-bound and has a large volume of distribution exceeding 15 L/kg, reflecting extensive tissue distribution including effective passage across the blood-brain barrier. The drug and its metabolites are excreted primarily in urine and bile. The pharmacokinetics of promethazine show considerable interindividual variability, which contributes to the variable clinical response seen among patients.
Therapeutic indications and uses
Allergic rhinitis and conjunctivitis
Promethazine is indicated for the symptomatic relief of seasonal and perennial allergic rhinitis. Patients suffering from hay fever or dust mite allergies experience improvements in sneezing, rhinorrhea, nasal itching, and congestion when treated with promethazine. The drug is also effective for allergic conjunctivitis, reducing ocular itching, tearing, and redness. Due to its prominent sedative effects, promethazine is not a first-line agent for routine allergy treatment but is often reserved for patients who require nighttime relief from allergic symptoms or who have not responded adequately to nonsedating antihistamines. Some patients find the sedative effect beneficial when allergic symptoms interfere with sleep.
Urticaria and angioedema
Acute and chronic urticaria respond well to promethazine therapy. The drug rapidly suppresses the wheal-and-flare response characteristic of hives, providing relief from pruritus and reducing the size and number of lesions. In acute urticaria associated with food allergies, drug reactions, or insect stings, promethazine can provide rapid symptom control. For chronic idiopathic urticaria, promethazine may be used when first-line therapies such as nonsedating antihistamines are insufficient. The drug is also used as adjunctive therapy for angioedema, though airway management and epinephrine remain the priorities in acute presentations.
Motion sickness and vestibular disorders
One of the most well-established indications for promethazine is the prevention and treatment of motion sickness. The drug is effective due to its combined antihistamine and anticholinergic effects, which suppress vestibular input to the vomiting center. Promethazine is most effective when taken prophylactically 30 to 60 minutes before exposure to motion. It is particularly useful for severe motion sickness that has not responded to simpler measures such as dimenhydrinate or meclizine. In vestibular disorders such as Meniere’s disease and vestibular neuritis, promethazine helps control acute vertigo and associated nausea. The drug’s sedative effects can be beneficial for patients who find the vertiginous episodes distressing or sleep-disrupting.
Postoperative nausea and vomiting
Promethazine is widely utilized in the perioperative setting for the prevention and treatment of postoperative nausea and vomiting. PONV is a common complication of anesthesia and surgery, affecting up to 30 percent of all surgical patients and as many as 80 percent of patients with multiple risk factors including female sex, nonsmoking status, history of motion sickness or PONV, and use of volatile anesthetics or opioid analgesics. Promethazine is effective for both prophylaxis and treatment of PONV and has the additional advantage of providing sedation that can promote rest in the immediate postoperative period. The drug can be administered orally, intramuscularly, or rectally for this indication.
Sedation and preoperative anxiolysis
The sedative properties of promethazine are utilized therapeutically in various clinical contexts. As a preoperative medication, promethazine reduces anxiety, promotes calmness, and decreases the amount of anesthetic agents needed during surgery. In pediatric populations, it has been used for sedation before minor procedures and diagnostic tests, though this practice has declined due to safety concerns and availability of alternative agents. In adults, promethazine is sometimes used as a short-term sleep aid, particularly when insomnia is related to allergic symptoms. The drug’s use as a routine hypnotic is limited by the rapid development of tolerance to its sedative effects and by its anticholinergic side effect profile.
Nausea and vomiting of pregnancy
Promethazine has been used for over six decades to treat nausea and vomiting associated with pregnancy, including hyperemesis gravidarum. While nonpharmacological measures and doxylamine-pyridoxine combinations are generally preferred as first-line therapy, promethazine remains a valuable option for women who require additional antiemetic therapy. The drug’s safety in pregnancy has been supported by extensive clinical experience, though it is classified as Pregnancy Category C and should be used when the potential benefit justifies the risk. Lower doses are generally used in pregnancy, and treatment duration should be as short as necessary.
Chemotherapy-induced nausea and vomiting
In oncology practice, promethazine is an adjunctive antiemetic for patients receiving chemotherapy. While highly emetogenic chemotherapy regimens are now typically managed with combinations of 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, and dexamethasone, promethazine can provide additional antiemetic coverage for breakthrough nausea and vomiting, particularly in the delayed phase that occurs days after chemotherapy administration. The drug is also useful for patients who cannot tolerate first-line antiemetics or who have persistent nausea despite optimal therapy. Promethazine’s sedative effects may be beneficial for patients experiencing fatigue and distress related to chemotherapy.
Other indications
Promethazine has been used for various other conditions. In anesthesiology, it is sometimes included in premedication cocktails for its combined sedative, antiemetic, and antisialagogue effects. In palliative care, promethazine’s antiemetic and sedative properties are utilized to manage nausea, vomiting, and terminal restlessness in patients with advanced illness. The drug has been used for intractable hiccups, leveraging its central depressant effects to interrupt the hiccup reflex arc. In some protocols for allergic transfusion reactions, promethazine is used as premedication. The drug has also been studied in the treatment of migraine headaches, though evidence for this indication is limited compared to other agents.
Dosage and administration
Adult dosing
The dosage of promethazine varies by indication and patient response. For allergic conditions in adults, the typical dose is 25 mg taken at bedtime, with an optional 12.5 mg dose before meals and at bedtime if daytime symptom control is needed. For motion sickness prevention, the recommended adult dose is 25 mg taken 30 to 60 minutes before departure, with a repeat dose 8 to 12 hours later if needed. For postoperative nausea and vomiting, 12.5 to 25 mg is typically administered one to two hours before the end of surgery or immediately postoperatively. For sedation, the usual adult dose is 25 to 50 mg. For general antiemetic use, 12.5 to 25 mg every 4 to 6 hours as needed, with a maximum daily dose of 100 mg.
Pediatric dosing
In pediatric patients aged two years and older, doses are adjusted based on age and weight. For allergies, 6.25 to 12.5 mg every 4 to 6 hours as needed, with a maximum of 25 mg per dose. Alternatively, a bedtime dose of 12.5 to 25 mg may be used. For motion sickness, 12.5 mg taken 30 to 60 minutes before travel, repeated every 12 hours as needed. For nausea and vomiting, 0.25 to 0.5 mg per kg of body weight every 4 to 6 hours as needed. The maximum daily dose in children should not exceed the adult dose of 100 mg. Promethazine is contraindicated in children under two years of age due to the risk of potentially fatal respiratory depression.
Geriatric considerations
Elderly patients are at increased risk for the adverse effects of promethazine, and the drug should generally be avoided in this population when alternatives exist. Older adults are more susceptible to sedation, dizziness, confusion, and anticholinergic effects including urinary retention, constipation, dry mouth, and blurred vision. The risk of falls and fractures is increased. The drug may worsen cognitive function in patients with dementia. When promethazine is necessary in an elderly patient, the lowest effective dose should be used, and patients should be monitored closely. Starting doses of 6.25 to 12.5 mg are recommended, with careful assessment before any dose increase.
Administration routes
Promethazine is available in multiple formulations. Oral tablets are the most common form for outpatient use and should be swallowed whole. The oral syrup formulation facilitates dose adjustment in pediatric patients and those who have difficulty swallowing tablets. Rectal suppositories are available for patients who cannot take oral medications due to nausea, vomiting, or other reasons. The injectable formulation is intended for deep intramuscular injection or intravenous administration and is typically used in hospital settings. Intravenous administration requires careful technique due to the risk of tissue injury from extravasation. Patients should be instructed to take the medication exactly as prescribed and not to exceed the recommended dose or frequency.
Side effects and adverse reactions
Common side effects
The most common side effect of promethazine is sedation, which affects the majority of patients to some degree. The sedation can range from mild drowsiness to deep sleepiness that impairs daily function. Tolerance to the sedative effect often develops within the first week of continued use but may not resolve completely. Anticholinergic effects including dry mouth, constipation, urinary retention, blurred vision, and reduced lacrimation are also common. Some patients experience photophobia and difficulty with visual accommodation. These effects are dose-dependent and may improve with dose adjustment.
Less common side effects
Gastrointestinal effects including nausea, vomiting, and epigastric discomfort have been reported. Some patients experience dizziness, tinnitus, and headache. Dermatological reactions including fixed drug eruption, photosensitivity, urticaria, and maculopapular rashes may occur. Endocrine effects including gynecomastia, galactorrhea, menstrual irregularities, and changes in libido have been associated with prolonged use due to the drug’s dopamine-blocking effects leading to elevated prolactin levels. Weight changes are not typically prominent but have been reported.
Central nervous system effects
In addition to sedation, promethazine can produce other CNS effects. Paradoxical CNS stimulation characterized by restlessness, agitation, anxiety, and insomnia occurs more frequently in children and elderly patients but can affect patients of any age. Extrapyramidal symptoms including acute dystonic reactions, akathisia, and parkinsonian symptoms have been reported, though the risk is lower than with antipsychotic phenothiazines due to promethazine’s weaker D2 antagonism. At high doses, CNS depression can progress to coma and respiratory depression. Seizures may occur in patients with preexisting seizure disorders or at toxic doses. Neuroleptic malignant syndrome, a rare but potentially fatal condition, has been associated with phenothiazine therapy.
Cardiovascular effects
Cardiovascular adverse effects include hypotension, particularly orthostatic hypotension, due to alpha-adrenergic receptor blockade. Tachycardia may occur as a compensatory response. QT interval prolongation has been associated with promethazine use, particularly at higher doses or with intravenous administration. The risk of torsades de pointes and other serious arrhythmias is increased in patients with preexisting cardiac disease, electrolyte abnormalities, or concurrent use of other QT-prolonging medications. Patients with known risk factors for QT prolongation should be monitored appropriately.
Serious adverse reactions
Respiratory depression is a serious concern, particularly in children, in patients with respiratory compromise, and when promethazine is combined with other CNS depressants. The occurrence of respiratory depression in children under two years of age prompted the contraindication in this age group. Severe tissue damage including necrosis, gangrene, and requiring surgical intervention can result from extravasation of intravenously administered promethazine. Agranulocytosis, leukopenia, and thrombocytopenia have been reported, usually with prolonged therapy. Cholestatic jaundice has occurred rarely. Anaphylactic reactions and angioedema, while rare, require immediate medical attention.
Contraindications and precautions
Absolute contraindications
Promethazine is contraindicated in children under two years of age due to the risk of respiratory depression. The drug should not be used in patients with known hypersensitivity to promethazine or any of its formulation components. It is contraindicated in patients with severe CNS depression or coma. Patients with narrow-angle glaucoma should not use promethazine due to the drug’s anticholinergic effects on intraocular pressure. The drug is contraindicated in patients with urinary retention conditions such as prostatic hypertrophy or bladder neck obstruction. It should not be used during acute asthmatic attacks. Concurrent therapy with monoamine oxidase inhibitors is contraindicated due to the risk of prolonged and intensified adverse effects.
Relative contraindications and precautions
Caution is required in patients with respiratory disease including asthma, COPD, and sleep apnea, as promethazine can suppress respiratory drive. In patients with cardiovascular disease, particularly preexisting arrhythmias, QT prolongation, or ischemic heart disease, the drug should be used with caution. Hepatic impairment may reduce promethazine clearance and require dose adjustment. Renal impairment may also necessitate dose adjustment. The drug lowers the seizure threshold and should be used cautiously in patients with epilepsy. Patients with depressed bone marrow function should be monitored for hematological toxicity. The presence of sulfites in some injectable formulations may cause allergic reactions in susceptible individuals.
Pregnancy and lactation
Promethazine has a long history of use in pregnancy, particularly for nausea and vomiting. The drug crosses the placenta, but fetal concentrations are generally lower than maternal concentrations. Large epidemiological studies have not demonstrated a consistent association between promethazine use during pregnancy and major birth defects. However, the drug should be used during pregnancy only when clearly needed. Promethazine is excreted in breast milk in small quantities and may cause drowsiness or irritability in nursing infants. The benefits of breastfeeding should be weighed against the potential risks to the infant when the mother requires promethazine therapy.
Drug interactions
Central nervous system depressants
The most significant drug interactions involving promethazine are with other CNS depressants. Alcohol, benzodiazepines, barbiturates, opioid analgesics, sedative-hypnotics, antipsychotics, other antihistamines, and muscle relaxants all have additive CNS depressant effects when combined with promethazine. This combination can result in deep sedation, respiratory depression, impaired cognitive function, and increased risk of accidents. Patients should be advised to avoid alcohol and to consult their healthcare provider before combining promethazine with any other CNS depressant medication.
Anticholinergic medications
Concurrent use of promethazine with other anticholinergic medications results in additive anticholinergic effects. Drugs with significant anticholinergic activity include tricyclic antidepressants, antispasmodics, antiparkinsonian medications, certain antipsychotics, antidiarrheal agents such as diphenoxylate-atropine combinations, and overactive bladder medications. Excessive anticholinergic effects can include severe constipation, urinary retention, blurred vision, dry mouth, hyperthermia, confusion, and cognitive decline. Elderly patients are particularly susceptible to these effects.
Qt-interval prolongation
Promethazine has been associated with QT interval prolongation, and the risk is increased when it is combined with other medications that prolong the QT interval. These include certain antiarrhythmics, macrolide and fluoroquinolone antibiotics, azole antifungals, tricyclic antidepressants, selective serotonin reuptake inhibitors, antipsychotics, and other antiemetics. The combination of multiple QT-prolonging medications can lead to potentially fatal cardiac arrhythmias including torsades de pointes. Electrolyte disturbances such as hypokalemia and hypomagnesemia further increase this risk.
Other interactions
Promethazine can reduce the effectiveness of dopamine agonists and levodopa due to its dopamine D2 receptor antagonism. The drug may potentiate the hypotensive effects of antihypertensive medications. Paradoxically, the combination of promethazine with epinephrine may result in hypotension rather than the expected pressor effect because promethazine’s alpha-adrenergic blocking properties can leave unopposed beta-adrenergic vasodilation. Promethazine may interfere with certain laboratory tests, including urinary pregnancy tests and certain immunoassays. The drug also has the potential to alter the metabolism of other medications through its effects on hepatic microsomal enzymes, though this is less clinically significant than with other phenothiazines.
Special populations
Pediatric use
The use of promethazine in children requires careful consideration. The drug is contraindicated in children under two years of age due to the risk of respiratory depression. In children aged two years and older, promethazine should be used with caution and at the lowest effective dose. Parents should be educated about the signs of respiratory depression including slow or shallow breathing, difficulty waking, and bluish skin coloration. Paradoxical CNS stimulation occurs more frequently in children than in adults and may present as hyperactivity, restlessness, irritability, and insomnia. The use of promethazine for routine sedation in children is not recommended, and alternative agents should be considered for conscious sedation during procedures.
Geriatric use
The use of promethazine in elderly patients is associated with increased risks of sedation, cognitive impairment, anticholinergic toxicity, orthostatic hypotension, and falls. The drug’s anticholinergic effects may worsen memory and cognitive function in patients with age-related cognitive decline or dementia. The Beers Criteria, which guides potentially inappropriate medication use in older adults, lists first-generation antihistamines including promethazine as potentially inappropriate for use in elderly patients. When promethazine is necessary, the lowest effective dose should be used, and the patient should be monitored closely for adverse effects. Alternative treatments should always be considered first.
Hepatic and renal impairment
Promethazine is metabolized in the liver, and patients with hepatic impairment may have reduced drug clearance leading to higher plasma concentrations and increased risk of toxicity. Dose reduction should be considered in patients with significant liver disease. While renal excretion is not the primary route of elimination, patients with severe renal impairment may have altered drug disposition, and caution is warranted. The pharmacokinetics of promethazine in patients with renal impairment have not been studied, and conservative dosing is recommended.
Clinical pharmacology in depth
Promethazine is a phenothiazine derivative with the chemical designation dimethylamino-2-propyll-10H-phenothiazine derivative. Its molecular formula is C17H20N2S, and its molecular weight is 284.4 g/mol. The phenothiazine core comprises a three-ring structure with sulfur at position 5 and nitrogen at position 10, with an aliphatic side chain at the nitrogen that determines the drug’s pharmacological properties. Unlike antipsychotic phenothiazines such as chlorpromazine that have a propylamine side chain, promethazine has an isopromethazine side chain that reduces its dopamine D2 receptor affinity relative to its H1 antihistamine activity.
The binding affinity of promethazine for the H1 receptor is in the nanomolar range, making it a potent antihistamine. Its affinity for muscarinic receptors is moderate, while its affinity for D2 receptors is lower than that of antipsychotic phenothiazines but sufficient to produce clinically relevant antiemetic effects. The drug also has affinity for alpha-adrenergic receptors, which contributes to its hypotensive effects, and for 5-HT2A serotonin receptors, though this effect is relatively weak. The broad receptor binding profile of promethazine explains both its diverse therapeutic applications and its wide range of potential adverse effects.
Metabolism of promethazine occurs primarily in the liver through N-demethylation, sulfoxidation, and conjugation pathways. The N-demethylation is mediated by CYP2B6 and CYP2C19, while sulfoxidation is mediated by flavin-containing monooxygenases. The major metabolite, promethazine sulfoxide, has been shown to retain some pharmacological activity and may contribute to both therapeutic and adverse effects. The terminal elimination half-life ranges from 9 to 16 hours, with a mean of approximately 12 hours. The half-life may be prolonged in elderly patients and those with hepatic impairment. Steady-state concentrations are achieved within approximately 2 to 3 days of regular dosing.
Comparison with other antihistamines
Promethazine differs from second-generation antihistamines such as loratadine, cetirizine, fexofenadine, and levocetirizine in several important respects. First-generation antihistamines like promethazine are lipophilic molecules that readily cross the blood-brain barrier, producing significant sedation due to blockade of central H1 receptors. Nonsedating antihistamines are substrates for P-glycoprotein efflux transporters that actively pump them out of the brain, limiting their CNS penetration. Also, promethazine has anticholinergic, antidopaminergic, and antiadrenergic properties that are not shared by newer antihistamines. These differences make promethazine more effective for conditions such as motion sickness and nausea and increase its side effect burden compared to newer agents.
Compared to other first-generation antihistamines, promethazine has a distinctive profile. Diphenhydramine has similar sedative and anticholinergic properties but lacks the antiemetic efficacy of promethazine. Dimenhydrinate is primarily used for motion sickness and has less antihistamine activity. Chlorpheniramine is less sedating and has fewer anticholinergic effects than promethazine and has less antiemetic activity. Cyproheptadine has antiserotonergic properties not shared by promethazine. The choice among first-generation antihistamines depends on the specific clinical indication and the desired balance of therapeutic effects and side effects.
Patient education and counseling
Patients prescribed promethazine require thorough education to ensure safe and effective use. The most critical counseling point is the drug’s potential to cause significant sedation and impairment of cognitive and motor function. Patients should be warned not to drive, operate machinery, or engage in hazardous activities until they understand how the medication affects them. The additive effects of alcohol and other CNS depressants should be emphasized. Patients should be advised to take the medication as prescribed and not to exceed the recommended dose.
For patients using promethazine for motion sickness, instructions should emphasize the importance of taking the medication prophylactically before travel. The drug should be taken 30 to 60 minutes before departure for optimal effect. Patients using the rectal suppository formulation should be given clear instructions on proper insertion technique. Those who experience significant dry mouth can be advised on measures such as increased fluid intake, sugarless gum, and good oral hygiene. Patients should be informed about the signs of serious adverse effects including difficulty breathing, severe dizziness, rapid or irregular heartbeat, and symptoms of allergic reactions, and advised to seek immediate medical attention if these occur. For convenient access to promethazine, patients may visit Happy Family Store for over-the-counter purchase.
Frequently asked questions
Can promethazine be used for sleep?
Promethazine is sometimes used as a sleep aid due to its sedative properties. However, it is not approved for this indication and is not recommended for routine treatment of insomnia. The drug’s anticholinergic effects and potential for tolerance to the sedative effect limit its utility for this purpose. Safer and more effective options for insomnia are available.
Is promethazine the same as phenergan?
Yes, Phenergan is a brand name for promethazine. Promethazine is the generic name of the active pharmaceutical ingredient. Generic promethazine is bioequivalent to brand-name Phenergan and is typically less expensive. Both contain the same active medication and have the same therapeutic effects and side effects.
Can promethazine be used for anxiety?
While promethazine’s sedative effects may provide some calming effects, it is not approved for the treatment of anxiety disorders. The drug’s sedation is not equivalent to targeted anxiolytic therapy, and tolerance to this effect develops rapidly. Patients with anxiety should consult their healthcare provider about appropriate treatments.
How long does promethazine stay in your system?
The elimination half-life of promethazine ranges from 9 to 16 hours in most adults. It takes approximately 5 half-lives for a drug to be eliminated from the body, meaning promethazine can be detected in the body for approximately 2 to 4 days after the last dose. Factors such as age, liver function, and concurrent medications can affect the elimination time.
Can i take promethazine every day?
Promethazine can be taken daily as prescribed for conditions that require continuous therapy, such as chronic urticaria. However, daily use should be under medical supervision, and the lowest effective dose should be used. Tolerance to the sedative effects may develop with daily use. Long-term daily use of promethazine carries risks of anticholinergic toxicity, particularly in elderly patients.
Is promethazine safe during pregnancy?
Promethazine has been used during pregnancy for many years, particularly for nausea and vomiting. While large studies have not found strong evidence of harm, the drug should be used during pregnancy only when the potential benefit justifies the potential risk. Pregnant women should discuss the risks and benefits with their healthcare provider.
Can promethazine cause weight gain?
Weight gain is not a consistently reported side effect of promethazine, unlike some other medications. Some patients may experience appetite changes, but significant weight gain is less common with promethazine than with agents such as cyproheptadine that have specific appetite-stimulating properties.
Storage and handling
Promethazine should be stored at room temperature, typically between 20 and 25 degrees Celsius, in a dry place protected from light. The medication should be kept in its original container with the lid tightly closed. All formulations should be stored out of reach of children and pets. The suppository formulation should be stored in a cool location but should not be frozen unless specifically directed. Liquid formulations should not be frozen. Expired or unused medication should be disposed of properly, ideally through pharmacy take-back programs, to prevent accidental ingestion or environmental contamination.